INTRODUCTION
Early reports of higher complication rates, specifically bile duct injuries, raised concerns over the safety of laparoscopy over open cholecystectomy. This study aims to ascertain the rate, management and perioperative outcomes of bile duct injury in an era beyond the laparoscopic learning curve.
METHODS
Following IRB and New York State (NYS) approval, the NYS Planning and Research Cooperative System (SPARCS) longitudinal administrative database was used to identify patients. SPA
Objective: Laparoscopic Cholecystectomy (LC) is one of the most commonly performed operations by general surgeons. Despite well-described technical recommendations, we hypothesize the operative approach to vary in clinical practice. The objective of our study was to provide a real-time snapshot of how LC is currently being performed by practicing surgeons.
Methods: We sent an online survey to surgeons regarding their approach to LC. Items surveyed included the ability to identify the critical
Background: A dearth of literature exists concerning the association between distinct comorbidities and resource utilization in patients undergoing cholecystectomy. This study aimed to review resource utilization trends of laparoscopic and open cholecystectomies from a comprehensive payer database in order to characterize patient factors associated with increased resource utilization. As healthcare payment models move towards bundled payments, group pricing, and Accountable Care Organizations (
Introduction: Laparoscopic cholecystectomy is the standard of care for treatment of benign biliary disease. However with declining reimbursements and increasing medical costs, it is imperative for physicians to examine closely their choices for equipment to decrease overall costs, particularly looking at key steps of cholecystectomy. The objective of this study was to examine variations between surgeons in equipment and operating room costs for elective laparoscopic cholecystectomy (LC).
Method
BACKGROUND: Stage IV melanoma has a high mortality rate. Traditional systemic therapies have shown limited benefit; however, several immunotherapies including cytokine therapies and checkpoint inhibitors have shown promise. Unfortunately, these immunotherapies are effective in only a small number of patients (pts), are non-specific and often toxic. We investigated a non-toxic and active specific form of immunotherapy, our dendritoma vaccine (DV), in late stage melanoma pts in a phase I/IIa trial